| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
797.75(M) |
| Last
Volume: |
4,409,980 |
Avg
Vol: |
4,464,222 |
| 52
Week Range: |
$4.5 - $8.81 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 455 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
16,866 |
495,199 |
| Total Sell Value |
$0 |
$0 |
$135,363 |
$5,999,241 |
| Total People Sold |
0 |
0 |
2 |
9 |
| Total Sell Transactions |
0 |
0 |
2 |
14 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Thackray Helen M. |
Chief R&D Officer |
• • – |
2024-03-31 |
4 |
D |
$5.08 |
$38,227 |
D/D |
(7,525) |
242,139 |
|
- |
|
| Milano Vincent |
Director |
• • – |
2024-02-29 |
4 |
A |
$5.63 |
$5,624 |
D/D |
999 |
51,997 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2024-02-29 |
4 |
A |
$5.63 |
$5,624 |
D/D |
999 |
51,860 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2024-01-03 |
4 |
GA |
$0.00 |
$0 |
I/I |
20,000 |
20,000 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2024-01-03 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
1,094,770 |
|
- |
|
| Gayer Charles K |
Chief Commercial Officer |
• • – |
2023-12-19 |
4 |
D |
$6.05 |
$15,016 |
D/D |
(2,482) |
274,533 |
|
- |
|
| Barnes Alane P |
Chief Legal Officer |
• • – |
2023-12-19 |
4 |
D |
$6.05 |
$15,016 |
D/D |
(2,482) |
293,539 |
|
- |
|
| Doyle Anthony |
Chief Financial Officer |
• • – |
2023-12-19 |
4 |
D |
$6.05 |
$15,016 |
D/D |
(2,482) |
227,444 |
|
- |
|
| Thackray Helen M. |
Chief R&D Officer |
• • – |
2023-12-19 |
4 |
D |
$6.05 |
$33,759 |
D/D |
(5,580) |
249,664 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2023-12-19 |
4 |
D |
$6.05 |
$85,238 |
D/D |
(14,089) |
1,114,770 |
|
- |
|
| Gayer Charles K |
Chief Commercial Officer |
• • – |
2023-12-14 |
4 |
D |
$6.43 |
$37,551 |
D/D |
(5,840) |
277,015 |
|
- |
|
| Gayer Charles K |
Chief Commercial Officer |
• • – |
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
282,855 |
|
- |
|
| Barnes Alane P |
Chief Legal Officer |
• • – |
2023-12-14 |
4 |
D |
$6.43 |
$25,816 |
D/D |
(4,015) |
296,021 |
|
- |
|
| Barnes Alane P |
Chief Legal Officer |
• • – |
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
64,000 |
300,036 |
|
- |
|
| Thackray Helen M. |
Chief R&D Officer |
• • – |
2023-12-14 |
4 |
D |
$6.43 |
$19,489 |
D/D |
(3,031) |
255,244 |
|
- |
|
| Thackray Helen M. |
Chief R&D Officer |
• • – |
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
51,000 |
258,275 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2023-12-14 |
4 |
D |
$6.43 |
$87,397 |
D/D |
(13,592) |
1,128,859 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
127,500 |
1,142,451 |
|
- |
|
| Doyle Anthony |
Chief Financial Officer |
• • – |
2023-12-14 |
4 |
D |
$6.43 |
$35,204 |
D/D |
(5,475) |
229,926 |
|
- |
|
| Doyle Anthony |
Chief Financial Officer |
• • – |
2023-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
34,000 |
235,401 |
|
- |
|
| Milano Vincent |
Director |
• • – |
2023-11-30 |
4 |
A |
$5.88 |
$5,621 |
D/D |
956 |
50,998 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2023-11-30 |
4 |
A |
$5.88 |
$5,621 |
D/D |
956 |
50,861 |
|
- |
|
| Heggie Theresa |
Director |
• • – |
2023-08-31 |
4 |
A |
$7.11 |
$5,624 |
D/D |
791 |
49,905 |
|
- |
|
| Milano Vincent |
Director |
• • – |
2023-08-31 |
4 |
A |
$7.11 |
$5,624 |
D/D |
791 |
50,042 |
|
- |
|
| Sanders Machelle |
Director |
• • – |
2023-06-15 |
4 |
S |
$7.98 |
$31,920 |
D/D |
(4,000) |
25,611 |
|
29% |
|
475 Records found
|
|
Page 1 of 19 |
|
|
0.17 (3.88%) 
